0
Oric Pharmaceuticals Banner Image

Oric Pharmaceuticals

  • Ticker ORIC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Oric Pharmaceuticals Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatmentMore regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.
Oric Pharmaceuticals

Most Recent Annual Report

Oric Pharmaceuticals
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Oric Pharmaceuticals Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!